First Mounjaro, Now Yurpeak: Eli Lilly Ties up with Cipla to Bring Weight Loss Drug Under New Name

First Mounjaro, now Yurpeak: Eli Lilly ties up with Cipla to bring weight loss drug under new name

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the rights to distribute and promote the drug under the brand name Yurpeak.

Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug Yurpeak

New Delhi, Oct 23 (PTI) Homegrown drugmaker Cipla and Eli Lilly and Company (India) on Thursday announced an agreement to distribute and promote type 2 diabetes and chronic weight management drug tirzepatide under a new brand name, Yurpeak, in India.Tirzepatide was launched in India by Lilly in March 2025 under the brand name Mounjaro.Under the agreement, Cipla has the rights to distribute and promote Yurpeak, the second brand of tirzepatide in …

Cipla To Sell Eli Lilly's Weight-Loss Drug As Yurpeak In India

Eli Lilly's blockbuster weight loss drug has found a market in India under the brand name Yurpeak after the company signed a deal with Indian drug maker Cipla on Thursday. As per news agency Reuters, the companies have agreed to market the drug under as a separate brand in the country. The agreement allows Cipla to sell 'Yurpeak' after it has been manufactured by Lilly.

Eli Lilly and Cipla announce agreement to distribute and promote tirzepatide in India under the brand name Yurpeak

Eli Lilly and Company (Lilly) and Cipla have announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak. Under the agreement, Cipla has the rights to distribute and promote Yurpeak, the second brand of tirzepatide in India. The agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities where Lilly already has an established presence. Lilly wil…